Epidermolysis bullosa is a genetic disorder characterized clinically by blister formation from mechanical trauma. There are four main types with additional sub-types identified. There is a spectrum of severity, and within each type, one may be either midely or severely affected. Epidermolysis bullosa range from being a minor inconvenience requiring modification of some activities, to being completely disabling and, in some cases, fatal.

Friction causes blister formation, blisters can form anywhere on the surface of the skin, within the oral cavity and in more severe forms many also involve the external surface of the eyes, as well as the respiratory, gastrointestinal and genitourinary tracts. In some form of the dieases,disfiguring scars and disabling musculoskeletal deformities occur.

Market Dynamics

The increasing prevalence of epidermolysis bullosa globally, rising research and development activities, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the global epidermolysis bullosa market over the forecast period.

For instance, in March 2020, Abeona Therapeutics Inc., a gene and cell development company announced that the first patient treated in a pivotal phase III clinical trial evaluating EB - 101 gene therapy for recessive dystrophic epidermolysis bullosa.

Key features of the study:

• This report provides an in-depth analysis of the global epidermolysis bullosa market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global epidermolysis bullosa market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global epidermolysis bullosa market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epidermolysis bullosa market

Detailed Segmentation:

• Global Epidermolysis Bullosa Market, By Product Type:
  • Antibiotic
  • Analgesics
  • Others
• Global Epidermolysis Bullosa Market, By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Epidermolysis Bullosa Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Amryt Pharma.*
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Abeona Therapeutics
  • Castle Creek Pharmaceuticals
  • RegeneRx
  • Krystal Biotech
  • RHEACELL GmbH
  • Holostem Terapie Avanzate
  • StemRim/Shionogi
  • Phoenix Tissue Repair

“*” marked represents similar segmentation in other categories in the respective section.